Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
Ophthalmology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
Br J Ophthalmol. 2022 Oct;106(10):1355-1362. doi: 10.1136/bjophthalmol-2020-318547. Epub 2021 May 18.
BACKGROUND/AIMS: To investigate the long-term outcomes of cultivated oral mucosal epithelial transplantation (COMET) for fornix reconstruction in eyes with chronic cicatrising disease.
This retrospective cohort study involved 16 eyes of 15 patients who underwent COMET for symblepharon release and fornix reconstruction between June 2002 and December 2008. The mean postoperative follow-up period was 102.1±46.0 months (range: 32-183 months). The treated cicatrising disorders included ocular cicatricial pemphigoid (OCP, five eyes), thermal/chemical injury (three eyes) and other chronic diseases (seven eyes; including recurrent pterygium (two eyes), Stevens-Johnson syndrome (one eye) and graft-versus-host disease (one eye)). Ocular-surface appearance was evaluated before surgery, at 1, 4, 12 and 24 weeks postoperative, and then annually based on the previously reported scoring system. Main outcome measures included overall and disease-specific fornix-reconstruction success probabilities analysed by the Kaplan-Meier survival curve. Symblepharon/fornix-shortening recurrence at 24 weeks postoperative, and its relationship to long-term surgical success was also examined.
At 5 years postoperative, the mean±SD overall fornix-reconstruction success probability was 79.6%±10.7%, and success probability for thermal/chemical injury and OCP was 100% and 53.3%±24.8%, respectively (p=0.53, log-rank test). The 3-year success probability was significantly higher in the no-disease-recurrence group at 24 weeks postoperative (13 eyes) than in the disease-recurrence group (three eyes) (100% and 33.3%±27.2%, respectively) (p=0.0073, log-rank test).
COMET was found to be safe and effective for symblepharon release and long-term fornix reconstruction in eyes with chronic cicatrisation. Although the 5-year success probability differed depend on the underlying disease, ocular-surface appearance at 24 weeks postoperative is a factor for predicting long-term outcome.
背景/目的:研究培养的口腔黏膜上皮移植(COMET)治疗慢性瘢痕性疾病患者穹窿重建的长期效果。
本回顾性队列研究纳入了 2002 年 6 月至 2008 年 12 月期间接受 COMET 治疗以松解睑球粘连和重建穹窿的 15 例 16 只眼。平均术后随访时间为 102.1±46.0 个月(范围:32-183 个月)。治疗的瘢痕性疾病包括眼瘢痕性类天疱疮(OCP,5 只眼)、热/化学伤(3 只眼)和其他慢性疾病(7 只眼;包括复发性翼状胬肉(2 只眼)、Stevens-Johnson 综合征(1 只眼)和移植物抗宿主病(1 只眼))。术前、术后 1、4、12 和 24 周以及此后每年,根据先前报道的评分系统评估眼表外观。主要观察指标包括采用 Kaplan-Meier 生存曲线分析的总体和疾病特异性穹窿重建成功率。还检查了术后 24 周时的睑球粘连/穹窿缩短复发情况及其与长期手术成功的关系。
术后 5 年,平均±SD 的总体穹窿重建成功率为 79.6%±10.7%,热/化学伤和 OCP 的成功率分别为 100%和 53.3%±24.8%(p=0.53,对数秩检验)。术后 24 周时无疾病复发组(13 只眼)的 3 年成功率明显高于疾病复发组(3 只眼)(100%和 33.3%±27.2%)(p=0.0073,对数秩检验)。
COMET 治疗慢性瘢痕性疾病患者的睑球粘连松解和长期穹窿重建是安全有效的。尽管 5 年成功率因基础疾病而异,但术后 24 周的眼表外观是预测长期结果的一个因素。